The world’s first spiral intraocular lens (IOL), unveiled at the ESCRS congress in Barcelona in September 2024, is now available to surgeons in Australia and New Zealand.
Following a large-scale multicentre data collection study, Rayner released the RayOne Galaxy and RayOne Galaxy Toric, marking a wider global rollout of its next-generation full range of focus IOLs.
RayOne Galaxy sets a new standard for what surgeons can offer their premium lens replacement patients. Developed with artificial intelligence (AI), its unique non-diffractive spiral optic delivers a smooth and continuous full range of vision with minimised dysphotopsia and 0% loss of transmitted light.1
Ten leading surgeons from ten countries conducted a pre-launch clinical evaluation, with over 180 eyes treated with RayOne Galaxy and RayOne Galaxy Toric – collecting postoperative clinical outcomes at one and three months. Interim outcomes show that RayOne Galaxy and RayOne Galaxy Toric provide:
- A full range of vision, without the wave-like defocus pattern associated with diffractive trifocal IOLs.
- Mean corrected and uncorrected visual acuities at all distances of 0.1 logMAR or better.1
- Binocular defocus curve VA of 0.2 logMAR or better across a ~4.0 D range.1
- Less halo and glare compared to published data on diffractive trifocal IOLs.
- In a pre-clinical study of 30 subjects with healthy eyes, RayOne Galaxy demonstrated a halo size closer to that of an enhanced monofocal IOL than a diffractive trifocal IOL.2
Having implanted the RayOne Galaxy during Rayner’s pre-launch clinical phase, Dr Francesco Carones, who took part in the initial clinical evaluation, said “it was immediately apparent that this IOL can provide a very long range of focus with minimal compromises on the quality of night vision”.
“I think this IOL represents a significant step forward in the technologies available to provide patients with very reduced spectacle dependence following lens replacement for cataract or refractive purposes.”
The RayOne Galaxy and RayOne Galaxy Toric were available in a limited release phase to selective surgeons from October to December 2024, allowing Rayner to collect further valuable insights before the full commercial release.
With over 6,000 lenses now in the market, Tim Clover, Rayner CEO said, “The response and enthusiasm from our customers around the world has been phenomenal and we look forward to seeing more patients achieving excellent results with the world’s first spiral IOL”.
The RayOne Galaxy spiral IOL platform is now available to all surgeons, subject to local regulatory approval. Speak to your Rayner representative today or visit www.rayner.com/Galaxy to discover more.
References
- Rayner 2025. Data on file.
- Amon et al. ACMIT study. Presented at ESCRS 2024.
